Clinical Trial: A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of GenSci164 in Healthy Adult Participants in China (China)

China, Sept. 8 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of GenSci164 in Healthy Adult Participants in China'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131915

Registration Time: 2026/09/07

Type: Interventional study

Primary Sponsor: Peking Union Medical College Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=340014

Published by HT Digital Content Services with permission from Health ...